Neuropeptides and psoriasis

Giornale Italiano di Dermatologia e Venereologia

Volumn 142, Issue 5, 2007, Pages 479-488

  Lawlor, C ^a   Kirby, B ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Cytokines; Neuropeptides; Psoriasis

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; GAMMA INTERFERON; INTERLEUKIN 6; K 252A; NERVE GROWTH FACTOR; NEUROPEPTIDE; SOMATOMEDIN C; SOMATOSTATIN; SUBSTANCE P; VASOACTIVE INTESTINAL POLYPEPTIDE;

APOPTOSIS; CELL PROLIFERATION; CLINICAL PRACTICE; CLINICAL RESEARCH; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE COURSE; DISEASE SEVERITY; DRUG BINDING; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOREACTIVITY; IN VITRO STUDY; INFLAMMATORY CELL; KERATINOCYTE; LEUKOCYTE; MACROPHAGE; MAST CELL; MAST CELL DEGRANULATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PSORIASIS; REVIEW; SKIN INFLAMMATION; STRESS; T LYMPHOCYTE; TREATMENT INDICATION; TREATMENT OUTCOME; UPREGULATION;

EID: 37049000752     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Lebwohl M. Psoriasis. Lancet 2003;361:1197-204.
2. Bowcock AM, Krueger JG. Getting under the skin: immunogenetics of psoriasis. Nat Rev Immunol 2005;5:699-71.
3. Fortune DG, Richards HL, Griffiths CE. Psychological factors in psoriasis: consequences, mechanisms and interventions. Derm Clin 2005;23:681-94.
4. Farber EM, Lanigan SW, Boer J. The role of cutaneous sensory nerves in the maintenance of psoriasis. Int J Dermatol 1990;29:418-20.
5. Joseph T, Kurian J, Warwick DJ, Friedmann PS. Unilateral remission of psoriasis following traumatic nerve palsy. Br J Dermatol 2005;152:185-6.
6. Payan DG, Levine JD, Goetzl EJ. Modulation of immunity and hypersensitivity by sensory neuropeptides. J Immunol 1984;132:1601-4.
7. Macris N, Schiavi M, Camerino. Effect of hypothalamic lesions on immune processes in the guinea pig. Am J Physiol 1970;219:1205-9.
8. Tyrey L, Nalbandov V. Influence of anterior hypothalamic lesions on circulating antibody titres in rat. Am J Physiol 1972;222:179-85.
9. Jankovic B, Isakovic K. Neuroendocrine correlates of immune response. Effects of brain lesions on antibody production, Arthus reactivity and delayed hypersensitivity in the rat. Int Arch Allergy Appl Immunol 1973;45:360-72.
10. Brooks W, Cross T, Roszman L, Markesbery. Neuroimmunomodulation: neural anatomical basis for impairment and facilitation. Ann Neurol 1982;12:56-61.
11. Dewing SB. Remission of psoriasis associated with cutaneous nerve section. Arch Dermatol 1971;104:220-1.
12. Veale D, Farrell M, Fitzgerald O. Mechanism of joint sparing in a patient with unilateral psoriatic arthritis and a longstanding hemiplegia. Br J Rheumatol 1993;32:413-6.
13. Mulherin D, Bresnihan B, Fitzgerald O. Digital denervation associated with absence of nail and distal interphalangeal joint involvement in psoriatic arthritis. J Rheumatol 1995;22:1221-2.
14. Kane D, Lockhart JC, Balint PV, Mann C, Ferrell WR, McInnes IB. Protective effect of sensory denervation in inflammatory arthritis. Ann Rheum Dis 2005;64:325-7.
15. Perlman HH. Remission of psoriasis vulgaris from the use of nerve blocking agents. Arch Dermatol 1972;105:128-9.
16. Olgart L, Gazelius E, Brodin E, Nilsson G. Release of substance P like immunoreactivity from the dental pulp. Acta Physiol Scand 1977;101:510-2.
17. Matsuda H, Kawakita K, Kiso Y, Nakano T, Kitamura Y. Substance P induces granulocyte infiltration through degranulation of mast cells. J Immunol 1989;142:927-31.
18. Foreman J, Jordan C. Histamine release and vascular changes induced by neuropeptides. Agents Actions 1983;13:105-16.
19. Yano H, Wershil BK, Arizono N, Galli SJ. Substance P-induced augmentation of cutaneous vascular permeability and granulocyte infiltration in mice is mast cell dependent. J Clin Immunol 1989;84:1276-86.
20. Peranin A, Snyderman R, Malfroy B. Substance P primes human neutrophil activation: a mechanism for neurological regulation of inflammation. Biochem Biophys Res Commun 1989;161:520-4.
21. Bar-Shavit A, Goldman R, Stabinsky Y, Gottlieb P, Fridkin M, Teichberg VI et al. Enhancement of phagocytosis - a newly found activity of substance P residing in its N-terminal tetrapeptide sequence. Biochem Biophys Res Commun 1980;94:1445-51.
22. Marasco W, Showell H, Becker E. Substance P binds to the formylpeptide chemotaxis receptor on the rabbit netrophil. Biochem Biophys Res Commun 1981;99:1065-72.
23. Payan D, Brewster R, Goetzl I. Specific stimulation of human T lymphocytes by substance P. J Immunol 1983;131:1613-5.
24. Hanley M. Substance P antagonists. Trends Neurosci 1982;5:138.
25. Payan D, Brewster R, Goetzl E. Binding properties of the substance P neuropeptide receptors on IM-9 human lymphoblastoid cells. Fed Proc 1984;43.
26. Calvo CF, Chavenel G, Senik A. Substance P enhances IL-2 expression in activated T cells. J Immunol 1992;148:3498-504.
27. Villabianca AC, Murphy CI, Reid TW. Growth-promoting effects of substance P on endothelial cells in vitro. Synergism with calcitonin gene-related peptide, insulin and plasma factors. Circ Res 1994;75:1113-20.
28. Ansel J, Perry P, Brown J. Cytokine modulation of keratinocyte cytokines. J Invest Dermatol 1990;94:S101-7.
29. Paus R, Heinzelmann T, Robicsek S. Substance P stimulates murine epidermal keratinocyte proliferation and dermal mast cell degranulation in situ. Arch Dermatol Res 1995;287:500-2.
30. Katayama I, Bae SJ, Hamasaki Y, Igawa K, Miyazaki Y, Yokozeki H et al. Stress response, tachykinin and cutaneous inflammation. J Investig Dermatol Symp Proc 2001;6:81-6.
31. Naukkarinen A, Nickoloff BJ, Farber EM. Quantification of cutaneous sensory nerves and their substance P content in psoriasis. J Invest Dermatol 1989;92:126-9.
32. Eedy DJ, Johnston CF, Shaw C. Neuropeptides in psoriasis: an immunocytochemical and radioimmunoassay study. J Invest Dermatol 1991;96:434-8.
33. Al'Abadie MS, Senior HJ, Bleehen SS, Gawkrodger DJ. Neuropeptides and general neuronal markers in psoriasis - an immunohistochemical study. Clin Exp Dermatol 1995;20:384-9.
34. Chan J, Smoller BR, Raychaudhuri SP. Intraepidermal nerve fiber expression of calcitonin gene-related peptide, vasoactive intestinal peptide and substance P in psoriasis. Arch Dermatol Res 1997;289:611-6.
35. Pincelli C, Fantini F, Romualdi P. Substance P is diminished and vasoactive intestinal peptide is augmented in psoriatic lesions and these peptides exert disparate effects on the proliferation of cultured human keratinocytes. J Invest Dermatol 1992;98:421-7.
36. Jiang W, Raychaudhuri S, Farber E. Double-labeled immunoflourescence study of cutaneous nerves in psoriasis. Int J Dermatol 1998;37:572-4.
37. Reichlin S. Somatostatin. N Engl J Med 1983;309:1495-501.
38. Wollina U, Mahrle G. Epidermal Merkel cells in psoriatic lesions: immunohistochemical investigations on neuroendocrine antigen expression. J Dermatol Sci 1992;3:145-50.
39. Theoharides TC, Douglas WW. Somatostatin induces histamine secretion from rat peritoneal mast cells. Endocrinololgy 1978;102:1637-40.
40. Diel F, Bethge N, Orpree W. Histamine secretion in leukocye incubates of patients with allergic hyper-rectivity induced by somatostatin 14 and somatostatin 28. Agents Actions 1983;13:216-8.
41. Theoharides T, Douglas W. Mast cell histamine secretion in response to somatostatin analogues: structural considerations. Eur J Pharmacol 1981;73:131-6.
42. Randic M, Miletic V. Depressant actions of methionine-enkephalin and somatostatin in cat dorsal horn neurones activated by noxious stimuli. Brain Res 1978;152:196-202.
43. Gazelius B, Brodin E, Olgart L, Panopoulos. Evidence that substance P is a mediator of antidromic vasodilatation using somatostatin as a release inhibitor. Acta Physiol Scand 1981;113:155-9.
44. Payan D, Brewster D, Goetzl E. Inhibition by somatostatin of the proliferation of T lymphocytes and Molt-4 lymphoblasts. Cell Immunol 1984.
45. Talme T, Ivanoff J, Sundqvist KG. Somatostatin is a specific inhibitor of SDF-1alpha-induced T cell infiltration. Clin Exp Immunol 2004;135:434-9.
46. Karalis K, Mastorakos G, Chrousos GP, Tolis G. Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 1994;93:2000-6.
47. Matt LH, Kingston TP, Lowe NJ. Treatment of severe psoriasis with intravenous somatostatin. J Dermatolog Treat 1989:181:81-2.
48. nd ed. New York: Marcel Dekker Inc.;1991. p. 829-46.
49. Bhatena S, Louie J, Scheitter G, Redman R, Wahl L, Recant L. Identification of human mononuclear leukocytes bearing receptors for somatostatin and glucagons. Diabetes 1981;30:127-31.
50. Hagstromer L, Emstestam L, Stridsberg M, Talme T. Expression pattern of somatostatin receptor subtypes 1-5 in human skin: an immunohistochemical study of healthy subjects and patients with psoriasis or atopic dermatitis. Exp Dermatol 2006;15:950-7.
51. Johansson O, Hilliges M, Talme T, Marcusson JA, Wetterberg L. Somatostatin immunoreactive cells in lesional psoriatic human skin-during peptide T treatment. Acta Derm Venereol 1994;74:106-9.
52. Cheng L, Khan M, Mudge AW. Calcitonin gene-related peptide promotes Schwann cell proliferation. J Cell Biol 1995;129:789-96.
53. Haegerstrand A, Dalsgaard CJ, Jonzon B. Calcitonin gene-related peptide stimulates proliferation of human endothelial cells. Proc Natl Acad Sci USA 1990;87:3299-303.
54. Brain SD. Williams TJ. Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability. Br J Pharmacol 1985;86:855-60.
55. O'Halloran DH, Bloom SR. Calcitonin gene related peptide. BMJ 1991;302:739-40.
56. Asahina A, Moro O, Hosoi J. Specific induction of cAMP in Langerhans cells by calcitonin gene-related peptide: relevance to functional effects. J Dermatol Sci 1998;20:21-8.
57. Hosoi J, Murphy GF, Egan CL. Regulation of Langerhans cell function by nerves containing calcitonin-gene related peptide. Nature 1993;363:159-63.
58. Torii H, Tamaki K, Granstein RD. The effect of neuropeptides/hormones on Langerhans cells. J Dermatol Sci 1998;20:21-8.
59. Yu XJ, Li CY, Wang KY, Dai HY. Calcitonin gene-related peptide regulates the expression of vascular endothelial growth factor in human HaCaT keratinocytes by activation of ERK1/2 MAPK. Regul Pept 2007;137:134-9.
60. Harvima IR, Viinamaki H, Naukkarinen A. Association of cutaneous mast cells and sensory nerves with psychic stress in psoriasis. Psychother Psychosom 1993;60:168-76.
61. Snider WD. Functions of the neurotrophins during nervous system development: what the knockouts are teaching us. Cell 1994;77:627-38.
62. Johnson D, Lanahan A, Buck CR. Expression and structure of the human NGF receptor. Cell 1986;47:545-54.
63. Raychaudhuri SK, Raychaudhuri SP, Weltman H. Effect of nerve growth factor on endothelial cell biology: proliferation and adherence molecule expression on human dermal microvascular endothelial cells. Arch Dermatol Res 2001;293:291-5.
64. Bischoff SC, Dahinden CA. Effect of nerve growth factor on the release of inflammatory mediators by mature human basophils. Blood 1992;79:2662-9.
65. Raychaudhuri SP, Jiang WY, Smoller BR, Farber EM. Nerve growth factor and its receptor system in psoriasis. Br J Dermatol 200;143:198-200.
66. Raychaudhuri SP, Jiang WY, Farber EM. Psoriatic keratinocytes express high levels of nerve growth factor. Acta Derm Venereol (Stockh) 1998;78:84-6.
67. Fantini F, Magnoni C, Bracci-Laudiero L. Nerve growth factor is increased in psoriatic skin. Invest Dermatol 1995;105:854-5.
68. Raychaudhuri SP, Farber EM. Neuroimmunologic aspects of psoriasis. Cutis 2000;66:357-62.
69. Nakamura M, Toyoda M, Morohashi M. Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br J Dermatol 2003;149:718-30.
70. Pincelli C, Marconi A. Autocrine nerve growth factor in human keratinocytes. J Dermatol Sci 2000;22:71-9.
71. Pincelli C. Nerve growth factor and keratinocytes: a role in psoriasis. Eur J Dermatol 2000;10:85-90.
72. Raychaudhuri SP, Sanyal M, Weltman H, Kundu-Raychaudhuri S. K252a, a high-affinity nerve growth factor receptor blocker, improves psoriasis: an in vivo study using the severe combined immunodeficient mouse-human skin model. J Invest Dermatol 2004;122:812-9.
73. Lindsay RM, Harmar AJ. Nerve growth factor regulates expression of neuropeptides expression of neuropeptide genes in adult sensory neurons. Nature 1989;337:362-4.
74. Bellinger DL, Lorton D, Brouxhon S. The significance of vasoactive intestinal polypeptide in immunomodulation. Adv Neuroimmunol 1996;6:5-27.
75. Nilsson SF, Maepea O. Comparison of the vasodilatory effects of vasoactive intestinal polypeptide (VIP) and peptide-HI (PHI) in the rabbit and the cat. Acta Physiol Scand 1987;129:17-26.
76. Ganea D, Sun L. Vasoactive intestinal peptide downregulates the expression of IL-2 but not of IFN gamma from stimulated murine T lymphocytes. J Neuroimmunol 1993;47:147-58.
77. Kakurai M, Fujita N, Murata S. Vasoactive intestinal peptide regulates its receptor expression and functions of human keratinocytes via type 1 vasoactive intestinal peptide receptors. J Invest Dermatol 2001;116:743-9.
78. Fortune DG, Richards DL, Main DJ, Griffiths CEM. What patients with psoriasis believe about their condition. J Am Acad Dermatol 1998;39:196-291.
79. Seville RH. Psoriasis and stress. Br J Dermatol 1977;97:297-302.
80. Fortune DG, Richards HL, Kirby B. Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch Dermatol 2003:139:752-6.
81. Fortune DG, Richards HL, Kirby B, Bowcock S, Main CJ, Griffiths CE. A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol 2002;146:458-65.
82. Richards HL, Ray DW, Kirby B, Mason D, Plant D, Main CJ et al. Response of the hypothalamic-pituitary-adrenal axis to psychological stress in patients with psoriasis. Br J Dermatol 2005;153:1114-20.
83. Buske-Kirschbaum A, Ebrecht M, Kern S, Hellhammer DH. Endocrine stress responses in TH1-mediated chronic inflammatory skin disease (psoriasis vulgaris)-do they parallel stress-induced endocrine changes in TH2-mediated inflammatory dermatoses (atopic dermatitis)? Psychoneuroendocrinology 2006;31:439-46.
84. Farber EM, Nickoloff BJ, Recht B, Fraki JE. Stress, symmetry and psoriasis: possible role of neuropeptides. J Am Acad Dermatol 1986;14:305-11.
85. Pisarchik A, Slominski A. Molecular and functional characterisation of novel CRFR1 isoforms in the skin. Eur J Biochem 2004;271:2821-30.
86. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Eng J Med 1995;332:1351-62.
87. Karalis K, Sano H, Redwine J, Listwak S, Wilder RL, Chrousos GP. Autocrine or paracrine inflammatory actions of corticotrophin-releasing hormone in vivo. Science 1991;254:421-3.
88. Slominski A, Wortsman J, Luger T, Paus R, Solomon S. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev 2000;80:979-1020.
89. O'Kane M, Murphy EP, Kirby B. The role of corticotrophin-releasing hormone in immune-mediated cutaneous inflammatory disease. Exp Derm 2006;15:143-53.
90. Merchenthaler I, Hynes MA, Vingh S, Schallly AV, Petrusz P. Immunocytochemical localization of corticotopin-releasing factor (CRF) in the rat spinal cord. Brain Res 1983;275:373-7.
91. Sckofitsch G, Zamir N, Heike CJ, Savitt JM, Jacobowitz DM. Cor-ticotropin-releasing factor-like immunoreactivity in sensory ganglia and capsaicin sensitive neurons of the rat central nervous system: colocalization with other neuropeptides. Peptides 1985;6:307-18.
92. Suda T, Tomori N, Tozawa F, Mouri T, Demura H, Shizume K. Distribution and characterization of immunoreactive corticotrophin-releasing factor in human tissues. J Clin Endocrinol 1984;59:861-6.
93. Kono M, Nagata H, Umemura S, Kawana S, Osamura RY. In situ expression of corticotopin-releasing hormone (CRH) and proopiomelanocortin (POMC) genes in human skin. FASEB J 2001;15:2297-9.
94. Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E et al. Corticotrophin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 1998;139:403-13.
95. Theoharides TC, Spanos CP, Pang X, Alferes L, Ligris K, Letourneau R et al. Stress-induced intracranial mast cell degranulation. A corticotrophin releasing hormone-mediated effect. Endocrinology 1995;136:5745-50.
96. th Annual Meeting of the American Society for Neuroscience, 1997, October 25-30, New Orleans (USA).
97. Murphy EP, McEvoy A, Conneely OM, Bresnihan B, FitzGerald O. Involvment of the nuclear orphan receptor NURR1 in the regulation of corticotrophin- releasing hormone expression and actions in human inflammatory arthritis. Arthritis Rheum 2001;44:782-93.
98. Maggi CA. The effects of tachykinins on inflammatory and immune cells. Regul Pept 1997;70:75-90.
99. Girolomoni G, Tigelaar RE. Capsaicin-sensitive primary sensory neurons are potent modulators of murine delayed type hypersensitivity reactions. J Immunol 1990;145:1105-12.
100. Bernstein JE, Parish LC, Rapaport M, Rosenbaum MM, Roenigk HH Jr. Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. J Am Acad Dermatol 1986;15:504-7.
101. Kikwai L, Babu RJ, Kanikkannan N, Singh M. Preformulation stability of Spantide II, a promising topical anti-inflammatory agent for the treatment of psoriasis and contact dermatitis. J Pharm Pharmacol 2004;56:19-25.
102. Farber EM, Cohen EN, Trozak DJ, Wilkinson DI. Peptide T improves psoriasis when infused into lesions in nanogram amounts. J Am Acad Dermatol 1991;25:658-64.